Topics:

IND Submitted for CYT-500

IND Submitted for CYT-500

PRINCETON, New Jersey—Cytogen Corporation has submitted an Investigational New Drug (IND) application to the FDA for CYT-500 for the treatment of hormone-refractory prostate cancer. CYT-500 targets prostate-specific membrane antigen (PSMA), which is abundantly expressed on the surface of prostate cancer cells. The agent incorporates the same monoclonal antibody used in Cytogen's ProstaScint (capromab pendetide) molecular imaging agent but is linked to a therapeutic payload.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.